Scienture Holdings Reports FY25 Financial Results, Provides Business Update

Scienture Holdings reported its year-end 2025 financial results and provided a business update. The company operates through Scienture, LLC, a branded specialty pharmaceutical company, and Integra Pharma Solutions, LLC, a pharmaceutical supplier. Scienture's assets in development include SCN-102 (cardiovascular), SCN-104 (CNS-Pain), SCN-105 (CNS), SCN-106 (cardiovascular), and SCN-107 (Pain). The company aims to provide value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the United States.